cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2012-2-13-18cardiovascular-1762Research ArticleАРТЕРИАЛЬНАЯ ГИПЕРТОНИЯARTERIAL HYPERTENSIONВзаимосвязь степени нарушений углеводного обмена с тяжестью артериальной гипертонии и липидным спектром у больных с метаболическим синдромомSeverity of carbohydrate metabolism disturbances, arterial hypertension stage, and lipid profile in patients with metabolic syndromeЖернаковаЮ. В.ZhernakovaYu. V.

(контактное лицо) — докторант отдела системных гипертензий

Тел.: 8 905-745-71-12

juli001@mail.ruЧазоваИ. Е.ChazovaI. E.

руководитель отдела, директор

Тел.: 8 905-745-71-12

juli001@mail.ruОлимпиеваС. П.OlimpievaS. P.

старший научный сотрудник кафедры медицинской кибернетики и информатики медико-биологического факультета РНИМУ им. Н. И. Пирогова

Тел.: 8 905-745-71-12

juli001@mail.ruКиликовскийВ. В.KilikovskyiV. V.

доцент кафедры медицинской кибернетики и информатики медико-биологического факультета РНИМУ им. Н. И. Пирогова

Тел.: 8 905-745-71-12

juli001@mail.ruИнститут клинической кардиологии им. А. Л. Мясникова ФГБУ Российский кардиологический научно-производственный комплекс Минздравсоцразвития России, МоскваA. L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex, Moscow2012200420121121318Copyright © Жернакова Ю.В., Чазова И.Е., Олимпиева С.П., Киликовский В.В., 20122012Жернакова Ю.В., Чазова И.Е., Олимпиева С.П., Киликовский В.В.Zhernakova Y.V., Chazova I.E., Olimpieva S.P., Kilikovskyi V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1762

Цель. Изучить взаимосвязь степени нарушений углеводного обмена, с тяжестью артериальной гипертонии (АГ): степень АГ и показатели суточного мониторирования артериального давления (СМАД) и липидного спектра. Материал и методы. Обследованы 403 пациента с АГ и метаболическим синдромом (МС), анализировали биохимические показатели крови, тест толерантности к глюкозе, СМАД. Результаты. У пациентов с нарушенным тестом толерантности к глюкозе (НТГ) по сравнению с пациентами с нарушением гликемии натощак (НГН) и тем более по сравнению с пациентами без явных нарушений углеводного обмена выявляются более тяжелые расстройства со стороны липидного спектра, они страдают более тяжелой степенью АГ, у них регистрируется достоверное повышение средних значений АД, нагрузки давлением и вариабельности АД по данным СМАД. Заключение. НТГ, являясь более тяжелым вариантом расстройства углеводного обмена, может сопровождаться увеличением риска сердечно-сосудистой заболеваемости и сахарного диабета 2 типа у таких больных.

Aim. To investigate the associations between the severity of carbohydrate metabolism disturbances, arterial hypertension (AH) severity (based on AH stage and 24-hour blood pressure monitoring (BPM) parameters), and lipid profile. Material and methods. In 403 patients with AH and metabolic syndrome (MS), blood biochemical assay, glucose tolerance test, and 24-hour BMP were performed. Results. Patients with impaired glucose tolerance (IGT), compared to participants with impaired fasting glycemia (IFG) or particularly to individuals with normal carbohydrate metabolism, demonstrated more severe lipid profile disturbances, more advanced AH stage, and increased mean BP levels, BP load, and BP variability at 24-hour BPM. Conclusion. IGT, as a more severe variant of carbohydrate metabolism disturbances, could be associated with increased risk of cardiovascular disease and Type 2 diabetes mellitus.

метаболический синдромартериальная гипертониягипергликемия натощакнарушение толерантности к углеводамmetabolic syndromearterial hypertensionfasting hyperglycemiaimpaired glucose toleranceReferencesDonahue RP, Orchard TJ. Hyperinsulinemia and resistance: association with cardiovasculars desease. Cardiovask risk factors 1993; 1: 12-8.Donahue RP, Orchard TJ. Hyperinsulinemia and resistance: association with cardiovasculars desease. Cardiovask risk factors 1993; 1: 12-8.Bjorntop P. “Portal” adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Aterosclerosis 1990; 10: 493-6.Bjorntop P. “Portal” adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Aterosclerosis 1990; 10: 493-6.Julius S, Gudbrandsson T, Jamerson K, et al. The hemodynamic link between insulin resistance and hypertension. J Hypertens 1991; 9: 983-6.Julius S, Gudbrandsson T, Jamerson K, et al. The hemodynamic link between insulin resistance and hypertension. J Hypertens 1991; 9: 983-6.DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European Studies. Diabetologia 1999; 42: 654-74.DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European Studies. Diabetologia 1999; 42: 654-74.UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13.UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13.Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999; 22: 920-4.Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999; 22: 920-4.Hanefeld M, Temelkova-Kurktschiev T, Schaper F, et al. Impaired fasting glucose is not a risk factor for atherosclerosis. Diabet Med 1999; 16: 212-8.Hanefeld M, Temelkova-Kurktschiev T, Schaper F, et al. Impaired fasting glucose is not a risk factor for atherosclerosis. Diabet Med 1999; 16: 212-8.DECODE Study Group, the European Diabetes Epidemiology Group Glucose tolerance and cardiovascular mortality: Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405.DECODE Study Group, the European Diabetes Epidemiology Group Glucose tolerance and cardiovascular mortality: Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405.DECODE Study Group, European Diabetes Epidemiology Group Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003; 26: 688-96.DECODE Study Group, European Diabetes Epidemiology Group Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003; 26: 688-96.Fisman EZ, Motro M, Tenenbaum A, et al. Impaired fasting glucose concentrations in nondiabetic patients with ischemic heart disease: A marker for a worse prognosis. Am Heart J 2001; 141: 485-90.Fisman EZ, Motro M, Tenenbaum A, et al. Impaired fasting glucose concentrations in nondiabetic patients with ischemic heart disease: A marker for a worse prognosis. Am Heart J 2001; 141: 485-90.Nigam A, Bourassa MG, Fortier A, et al. Fasting but not postprandial (postmeal) glycemia predicts the risk of death in subjects with coronary artery disease. Can J Cardiol 2007; 23 (11): 873-8.Nigam A, Bourassa MG, Fortier A, et al. Fasting but not postprandial (postmeal) glycemia predicts the risk of death in subjects with coronary artery disease. Can J Cardiol 2007; 23 (11): 873-8.Meigs JB, Nathan DM, D’Agostino RB, Wilson PWF, Framingham Offspring Study Fasting and postchallenge glycemia and cardiovascular disease risk: The Framingham Offspring Study. Diabetes Care 2002; 25: 1845-50.Meigs JB, Nathan DM, D’Agostino RB, Wilson PWF, Framingham Offspring Study Fasting and postchallenge glycemia and cardiovascular disease risk: The Framingham Offspring Study. Diabetes Care 2002; 25: 1845-50.Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998; 21: 360-7.Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998; 21: 360-7.Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men The Rancho Bernardo Study. Diabetes Care 1998; 21: 1236-9.Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men The Rancho Bernardo Study. Diabetes Care 1998; 21: 1236-9.Piche ME, Lemieux S, Perusse L, Weisnagel SJ. High normal 2-hour plasma glucose is associated with insulin sensitivity and secretion that may predispose to type 2 diabetes. Diabetologia 2005; 48: 732-40.Piche ME, Lemieux S, Perusse L, Weisnagel SJ. High normal 2-hour plasma glucose is associated with insulin sensitivity and secretion that may predispose to type 2 diabetes. Diabetologia 2005; 48: 732-40.Carnevale Schianca GP, Rossi A, Sainaghi PP, et al. The significance of impaired fasting glucose versus impaired glucose tolerance: Importance of insulin secretion and resistance. Diabetes Care 2003; 26: 1333-7.Carnevale Schianca GP, Rossi A, Sainaghi PP, et al. The significance of impaired fasting glucose versus impaired glucose tolerance: Importance of insulin secretion and resistance. Diabetes Care 2003; 26: 1333-7.Festa A, D’Agostino R, Hanley AJ, et al. Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes 2004; 53: 1549-55.Festa A, D’Agostino R, Hanley AJ, et al. Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes 2004; 53: 1549-55.Chazova I.E., Mychka V.B. Metabolic syndrome. Media Medica 2008; 319 p. Russian (Чазова И.Е., Мычка В.Б. Метаболический синдром. М.: Медиа Медика 2008; 319 c.).Chazova I.E., Mychka V.B. Metabolic syndrome. Media Medica 2008; 319 p. Russian (Чазова И.Е., Мычка В.Б. Метаболический синдром. М.: Медиа Медика 2008; 319 c.).Davis BR, Cutler JD, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996; 9: 342-60.Davis BR, Cutler JD, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996; 9: 342-60.Robertson RP, Olson LK, Zhang HJ, et al. Differentiating glucose toxity from glucose desensitization; a new message from insulin gene. Diabetes 1994; 43 (9): 1085-9.Robertson RP, Olson LK, Zhang HJ, et al. Differentiating glucose toxity from glucose desensitization; a new message from insulin gene. Diabetes 1994; 43 (9): 1085-9.Fraze E. Ambient plasma free fatty acid concentration in noninsulin-dependent diabetes mellitus: evidence for insulin resistance. J Clin Endocrin Metab 1995; 61: 405-9.Fraze E. Ambient plasma free fatty acid concentration in noninsulin-dependent diabetes mellitus: evidence for insulin resistance. J Clin Endocrin Metab 1995; 61: 405-9.

The authors declare that there are no conflicts of interest present.